OPKO initiates enrollment in Phase III CINV trials
The program is comprised of two randomized, double-blind and placebo controlled trials. One trial will evaluate the efficacy of a single 200mg oral dose of rolapitant in patients
The US Food and Drug Administration (FDA) is set to review Kowa Pharmaceuticals America’s new drug application (NDA) for K-911, an investigational once-daily eye drop aimed at reducing intraocular pressure (IOP) in open-angle glaucoma (OAG) or ocular hypertension (OHT) patients.